Related Experiment Videos
Lafora disease: a progressive myoclonus epilepsy.
E J Elliott1, I C Talbot, I F Pye
1Department of Child Health, University of Leicester, United Kingdom.
Journal of Paediatrics and Child Health
|December 1, 1992
Summary
Lafora disease, a rare metabolic disorder, causes progressive myoclonus epilepsy and intellectual decline due to polyglucosan accumulation. Skin biopsy offers a reliable, less invasive diagnostic method for this condition.
Area of Science:
- Neurology
- Metabolic Disorders
- Genetics
Background:
- Lafora disease is a rare, inherited metabolic disorder characterized by polyglucosan accumulation in various tissues.
- It leads to severe neurological symptoms, including progressive myoclonus epilepsy and intellectual deterioration.
Observation:
- Four children with Lafora disease presented with epilepsy and cognitive decline.
- Diagnostic confirmation involved liver biopsy (PAS positive, diastase resistant, colloidal iron staining inclusions) in two cases.
- Cerebellar biopsy confirmed the diagnosis in one child, with retrospective analysis revealing abnormal liver biopsy findings.
- Skin biopsy successfully diagnosed the condition in a fourth child, despite prolonged suggestive clinical and EEG findings.
Findings:
- The study highlights the diagnostic utility of liver and skin biopsies in Lafora disease.
- Skin biopsy is identified as a reliable and less invasive method for histological diagnosis.
- Autosomal recessive inheritance, progressive nature, and poor prognosis are characteristic of Lafora disease.
Implications:
- Increased pediatrician awareness of Lafora disease is crucial for timely diagnosis.
- Early histological diagnosis enables prognostic and genetic counseling.
- Prompt diagnosis facilitates optimal management and treatment strategies for affected individuals.